Tivic Health Advances FDA Drug Application With $4.1M Manufacturing Deal for Revolutionary Radiation Treatment Tivic partners with Scorpius for GMP validation of Entolimod, advancing unique radiation syndrome treatment toward FDA submission. Learn manufacturing details.

#TIVC #SCPX Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

www.stocktitan.net/news/TIVC/tivic-health-e...

Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal Scorpius Holdings (NYSE American: SCPX) has received a delisting notice from NYSE American due to the low selling price of its common stock. The company also received a non-compliance notice for failing to file its Form 10-K for the period ended December 31, 2024, by the April 15, 2025 deadline.The CDMO company cited time constraints on management and potential undue hardship and expense as reasons for the delayed filing in their Form 12b-25 notification. Scorpius plans to appeal the delisting decision and will request a review by the Exchange's Listings Qualifications Panel.CEO Jeff Wolf stated the company is actively working to achieve full compliance with SEC requirements and will provide updates as they become available. While the appeal's outcome remains uncertain, Scorpius maintains its commitment to transparency, regulatory compliance, and maximizing shareholder value.

#SCPX Scorpius Holdings Receives NYSE American Notice of Delisting and Reports Plans to Appeal

www.stocktitan.net/news/SCPX/scorpius-holdi...

Is Scorpius Holdings Preparing for a Sale? CDMO Taps Financial Advisor for Strategic Review The CDMO has engaged A.G.P. to evaluate potential transactions and strategic changes aimed at maximizing shareholder value in the competitive biologics sector.

#SCPX Scorpius Holdings Engages Alliance Global Partners to Explore Strategic Alternatives

www.stocktitan.net/news/SCPX/scorpius-holdi...

Scorpius Partners with KaloCyte on Revolutionary Artificial Blood Cell Manufacturing Scorpius Holdings teams with KaloCyte to optimize production of ErythroMer™, a universal artificial blood cell targeting a $7B market. Partnership could expand to full manufacturing.

#SCPX Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMer™

www.stocktitan.net/news/SCPX/scorpius-holdi...

NEWS: ( NYSE: #SCPX ) Scorpius Holdings Cancels Planned Reverse Stock Split

Scorpius Holdings Cancels Planned 1-for-20 Reverse Stock Split in Surprise Move Scorpius Holdings (SCPX), a biologics CDMO, has cancelled its previously announced reverse stock split, raising questions about its NYSE American listing compliance strategy.

#SCPX Scorpius Holdings Cancels Planned Reverse Stock Split

www.stocktitan.net/news/SCPX/scorpius-holdi...

Scorpius Holdings Announces 1-for-20 Reverse Stock Split to Maintain NYSE American Listing Scorpius Holdings implements reverse stock split effective January 21, 2025, aiming to meet NYSE American listing requirements. Shareholders retain proportional ownership.

#SCPX Scorpius Holdings Announces Reverse Stock Split

www.stocktitan.net/news/SCPX/scorpius-holdi...

#SCPX Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model

www.stocktitan.net/news/SCPX/scorpius-holdi...

#SCPX Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

www.stocktitan.net/news/SCPX/scorpius-holdi...